Table 2: Novo Nordisk gross and net sales globally Source: Novo Nordisk 2023 annual report Notably, Novo does not separate commercial health plans from Medicare in its filing, but Wegovys favorable commercial coverage does not appear to extend to Medicare plans and those on the health insurance exchange, which may reflect payers attempt to avoid adverse selection or a decision by the manufacturer to not rebate as heavily in this channel
11.2 Application of nanotechnology in CUL5-targeted therapy Given that CUL5 is widely involved in normal cellular physiological functions and its neddylation pathway partially overlaps with other Cullin family members (e.g., CUL1), existing targeting strategies often suffer from suboptimal specificity and are prone to off-target effects (18, 172)
The latest news on HYMPAVZI, with the FDA granting Priority Review to expand its hemophilia label, plugs into that narrative as a secondary but helpful catalyst: it reinforces Pfizer's push into highervalue specialty medicines, even if the nearterm financial impact looks modest next to a potential GLP1 launch
This syndrome can be treated with a gut-healing peptide such as BPC-157
